ClinicalTrials.gg
CompletedNCT02034513SWITCH 1Updated Jan 2, 2019Results posted

A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes

A Phase 3 interventional study of insulin degludec and insulin glargine in Diabetes and Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S. Completed at 99 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-02.

Primary conditionDiabetes Mellitus, Type 1Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 1
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 1, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
501
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing insulin degludec in Diabetes Mellitus, Type 1 — none open to participants now, none under way, none of them phase 3. insulin degludec · Diabetes Mellitus, Type 1.

Enrollment
2nd of 39
501 · median 38
Started
2014
the only one that year
Phase 3
7 of 39
none open now
Registered
28th of 39
by date
Lead sponsor
30 of 39
Novo Nordisk A/S

Among the 39 studies testing insulin degludec in Diabetes Mellitus, Type 1, this one is the 2nd largest by enrollment, is the only one that started in 2014, is one of 7 in phase 3, and was the 28th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

None of the 39 studies testing insulin degludec in Diabetes Mellitus, Type 1 is open now. The open studies under Diabetes Mellitus, Type 1, anywhere →

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies testing insulin degludec in Diabetes Mellitus, Type 1 as a file.
02

Study summary

This trial is conducted in Europe and the United States of America (USA). The aim of the trial is to compare the safety and efficacy of insulin degludec (IDeg) and insulin glargine (IGlar), both with insulin aspart (IAsp) as mealtime insulin in subjects with type 1 diabetes.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 1

Browse trials for

04

In context

Diabetes Mellitus, Type 1 Reclassified

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

This study's enrollment of 501 is above the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.

Browse Diabetes Mellitus, Type 1 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 1, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: - Subjects fulfilling at least one of the below criteria: a) Experienced at least one severe hypo episode within the last year (according to the ADA (American Diabetes Association) definition, April 2013) b) Moderate chronic renal failure, defined as 30 - 59 mL/min/1.73 m\^2 per CKD-Epi (chronic kidney disease epidemiology collaboration) c) Hypoglycaemic symptom unawareness d) Diabetes mellitus duration for more than 15 years e) Recent episode of hypoglycaemia (defined by symptoms of hypoglycaemia and/or episode with low glucose measurement (below or equal to 70 mg/dL [below or equal to 3.9 mmol/L])) within the last 12 weeks prior to Visit 1 (screening) - Male or female, age at least 18 years at the time of signing - Type 1 diabetes mellitus (diagnosed clinically) for at least 52 weeks prior to Visit 1 - Current treatment with a basal-bolus regimen consisting of neutral protamine Hagedorn (NPH) insulin OD (once daily) / BID (twice daily) or insulin detemir (IDet) OD / BID plus 2-4 daily injections of any rapid acting meal time insulin or CSII (with rapid acting insulin) for at least 26 weeks prior to Visit 1 - (glycosylated ) below or equal to 10% by central laboratory analysis - (body mass index) below or equal to 45 kg/m\^2 Exclusion Criteria: - Treatment with IGlar or IDeg within the last 26 weeks prior to Visit 1 (short term use [less than or equal to 2 weeks] is allowed, but not within 4 weeks prior to screening) - Use of any other anti-diabetic agent than those stated in the inclusion criteria within the last 26 weeks prior to Visit 1

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
501 participants (actual)

Study arms

  • Experimental
    IDeg OD + IAsp followed by IGlar OD + IAsp

    Each treatment period consists of a 16-week wash-out period and a 16-week maintenance period

    Drug: insulin degludec · Drug: insulin glargine · Drug: insulin aspart

  • Active comparator
    IGlar OD + IAsp followed by IDeg OD + IAsp

    Each treatment period consists of a 16-week wash-out period and a 16-week maintenance period

    Drug: insulin degludec · Drug: insulin glargine · Drug: insulin aspart

Interventions

  • Administered once daily, injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.

  • Administered once daily, injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.

  • Administered 2-4 times daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.

07

What researchers measure

Primary outcomes

  1. Number of Treatment Emergent Severe or BG (Blood Glucose) Confirmed Symptomatic Hypoglycaemic Episodes During the Maintenance Period

    Severe or blood glucose (BG) confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe and/or BG confirmed by a plasma glucose value of \<3.1 mmol/L (56 mg/dL), with symptoms consistent with hypoglycaemia. Treatment emergent hypoglycaemic episode was defined as an event with onset date on or after the first day of exposure to randomised treatment and no later than the last day of randomised treatment. Maintenance period: 16 weeks of treatment, in each treatment period (Week 16-32 and Week 48-64).

    Time frame: A 16-week treatment period.

Secondary outcomes

  1. Number of Treatment Emergent Severe or BG Confirmed Symptomatic Nocturnal Hypoglycaemic Episodes During the Maintenance Period

    Severe or BG confirmed symptomatic nocturnal hypoglycaemic episodes were defined as episodes that were severe and/or BG confirmed by a plasma glucose value of \<3.1 mmol/L (56 mg/dL), with symptoms consistent with hypoglycaemia and with time of onset between 00:01 and 05.59 a.m., both inclusive. Treatment emergent hypoglycaemic episode was defined as an event with onset date on or after the first day of exposure to randomised treatment and no later than the last day of randomised treatment.

    Time frame: After 16 weeks of treatment, in each treatment period (Week 16-32 and Week 48-64)

  2. Proportion of Subjects With One or More Severe Hypoglycaemic Episodes During the Maintenance Period

    Percentage of subjects who experienced one or more severe hypoglycaemic episodes during the maintenance period. Severe hypoglycaemia (according to the American Diabetes Association 2013 definition): A hypoglycaemic episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose values may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.

    Time frame: After 16 weeks of treatment, in each treatment period (Week 16-32 and Week 48-64)

  3. Incidence of Treatment Emergent Adverse Events

    Treatment emergent adverse event was defined as an event with onset date on or after the first day of exposure to randomised treatment and no later than the last day of randomised treatment.

    Time frame: During 32 weeks of treatment for each treatment period

  4. Change From Baseline in HbA1c (Glycosylated Haemoglobin)

    Change from baseline in HbA1c (glycosylated haemoglobin) at week 32 (treatment period 1) and at week 64 (treatment period 2). Week 32 HbA1c absolute value was considered as baseline for calculating change from baseline in HbA1c at week 64.

    Time frame: Week 32, Week 64

  5. FPG (Fasting Plasma Glucose)

    Fasting plasma glucose values at week 32 and week 64.

    Time frame: Week 32 and Week 64

08

Results

Posted May 15, 2017

Participant flow

The trial was conducted at 90 sites in 2 countries, as follows: US: 84 sites, Poland: 6 sites.

Participant flow — Overall Study
MilestoneInsulin Degludec/Insulin Glargine (IDeg/IGlar)Insulin Glargine/Insulin Degludec (IGlar/IDeg)
Started249252
Exposed249251
Completed200195
Not completed4957
Withdrew: Adverse event1110
Withdrew: Lack of efficacy01
Withdrew: Lost to follow-up67
Withdrew: Pregnancy03
Withdrew: Protocol violation710
Withdrew: Withdrawal by subject2525
Withdrew: Unclassified01

Outcome measures

PrimaryNumber of Treatment Emergent Severe or BG (Blood Glucose) Confirmed Symptomatic Hypoglycaemic Episodes During the Maintenance Period

Severe or blood glucose (BG) confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe and/or BG confirmed by a plasma glucose value of \<3.1 mmol/L (56 mg/dL), with symptoms consistent with hypoglycaemia. Treatment emergent hypoglycaemic episode was defined as an event with onset date on or after the first day of exposure to randomised treatment and no later than the last day of randomised treatment. Maintenance period: 16 weeks of treatment, in each treatment period (Week 16-32 and Week 48-64).

Time frame:
A 16-week treatment period.
Reported as:
Number · Event
Number of Treatment Emergent Severe or BG (Blood Glucose) Confirmed Symptomatic Hypoglycaemic Episodes During the Maintenance Period
EventInsulin Degludec (IDeg)Insulin Glargine (IGlar)
Number of Treatment Emergent Severe or BG (Blood Glucose) Confirmed Symptomatic Hypoglycaemic Episodes During the Maintenance Period27723126
Statistical analysis
  • Insulin Degludec (IDeg) vs Insulin Glargine (IGlar) · Poisson · p = <0.0001 · Treatment ratio: 0.89 · 95% CI 0.85 to 0.94If non-inferiority was confirmed the superiority of IDeg/IGlar was investigated outside of the test hierarchy. Superiority was considered confirmed if the upper bound of the 2-sided 95% confidence interval was \<1.00.
SecondaryNumber of Treatment Emergent Severe or BG Confirmed Symptomatic Nocturnal Hypoglycaemic Episodes During the Maintenance Period

Severe or BG confirmed symptomatic nocturnal hypoglycaemic episodes were defined as episodes that were severe and/or BG confirmed by a plasma glucose value of \<3.1 mmol/L (56 mg/dL), with symptoms consistent with hypoglycaemia and with time of onset between 00:01 and 05.59 a.m., both inclusive. Treatment emergent hypoglycaemic episode was defined as an event with onset date on or after the first day of exposure to randomised treatment and no later than the last day of randomised treatment.

Time frame:
After 16 weeks of treatment, in each treatment period (Week 16-32 and Week 48-64)
Reported as:
Number · Event
Number of Treatment Emergent Severe or BG Confirmed Symptomatic Nocturnal Hypoglycaemic Episodes During the Maintenance Period
EventInsulin Degludec (IDeg)Insulin Glargine (IGlar)
Number of Treatment Emergent Severe or BG Confirmed Symptomatic Nocturnal Hypoglycaemic Episodes During the Maintenance Period349544
Statistical analysis
  • Insulin Degludec (IDeg) vs Insulin Glargine (IGlar) · Poisson · p = <0.0001 · Treatment ratio: 0.64 · 95% CI 0.56 to 0.73If non-inferiority was confirmed the superiority of IDeg/IGlar was investigated outside of the test hierarchy. Superiority was considered confirmed if the upper bound of the 2-sided 95% confidence interval was \<1.00.
SecondaryProportion of Subjects With One or More Severe Hypoglycaemic Episodes During the Maintenance Period

Percentage of subjects who experienced one or more severe hypoglycaemic episodes during the maintenance period. Severe hypoglycaemia (according to the American Diabetes Association 2013 definition): A hypoglycaemic episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose values may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.

Time frame:
After 16 weeks of treatment, in each treatment period (Week 16-32 and Week 48-64)
Reported as:
Number · Percentage of subjects
Proportion of Subjects With One or More Severe Hypoglycaemic Episodes During the Maintenance Period
Percentage of subjectsInsulin Degludec (IDeg)Insulin Glargine (IGlar)
Proportion of Subjects With One or More Severe Hypoglycaemic Episodes During the Maintenance Period10.317.1
Statistical analysis
  • Insulin Degludec (IDeg) vs Insulin Glargine (IGlar) · McNemar · p = 0.0016 (Superiority was confirmed if the p-value was less than 0.025.)
SecondaryIncidence of Treatment Emergent Adverse Events

Treatment emergent adverse event was defined as an event with onset date on or after the first day of exposure to randomised treatment and no later than the last day of randomised treatment.

Time frame:
During 32 weeks of treatment for each treatment period
Reported as:
Number · Event
Incidence of Treatment Emergent Adverse Events
EventInsulin Degludec (IDeg)Insulin Glargine (IGlar)
Incidence of Treatment Emergent Adverse Events925937
SecondaryChange From Baseline in HbA1c (Glycosylated Haemoglobin)

Change from baseline in HbA1c (glycosylated haemoglobin) at week 32 (treatment period 1) and at week 64 (treatment period 2). Week 32 HbA1c absolute value was considered as baseline for calculating change from baseline in HbA1c at week 64.

Time frame:
Week 32, Week 64
Reported as:
Mean · Percentage of glycosylated haemoglobin
Change From Baseline in HbA1c (Glycosylated Haemoglobin)
Percentage of glycosylated haemoglobinInsulin Degludec/Insulin Glargine (IDeg/IGlar)Insulin Glargine/Insulin Degludec (IGlar/IDeg)
week 32 (n=209, 205)-0.73 ± 0.89-0.66 ± 0.76
week 64 (n=203, 199)0.04 ± 0.510.17 ± 0.64
Statistical analysis
  • Insulin Degludec/Insulin Glargine (IDeg/IGlar) vs Insulin Glargine/Insulin Degludec (IGlar/IDeg) · Treatment contrast: 0.03 · 95% CI -0.10 to 0.15
  • Insulin Degludec/Insulin Glargine (IDeg/IGlar) vs Insulin Glargine/Insulin Degludec (IGlar/IDeg) · Treatment contrast: 0.11 · 95% CI -0.00 to 0.23
SecondaryFPG (Fasting Plasma Glucose)

Fasting plasma glucose values at week 32 and week 64.

Time frame:
Week 32 and Week 64
Reported as:
Mean · mmol/L
FPG (Fasting Plasma Glucose)
mmol/LInsulin Degludec/Insulin Glargine (IDeg/IGlar)Insulin Glargine/Insulin Degludec (IGlar/IDeg)
week 32 (n=208, 204)7.45 ± 3.578.12 ± 3.56
week 64 (n=203, 201)8.62 ± 4.247.54 ± 3.68

Adverse events

Collected over From the first day of exposure to randomised treatment and no later than the last day of randomised treatment (64 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Insulin Degludec (IDeg)—58/454 (12.8%)97/454 (21.4%)
Insulin Glargine (IGlar)—70/460 (15.2%)97/460 (21.1%)
Most frequent serious events
Showing 10 of 63
Most frequent serious events
EventInsulin Degludec (IDeg)Insulin Glargine (IGlar)
HypoglycaemiaMetabolism and nutrition disorders17/45433/460
Hypoglycaemic unconsciousnessNervous system disorders18/45419/460
Hypoglycaemic seizureNervous system disorders3/4545/460
Accidental overdoseInjury, poisoning and procedural complications2/4543/460
Diabetic ketoacidosisMetabolism and nutrition disorders2/4543/460
PneumoniaInfections and infestations2/4543/460
CellulitisInfections and infestations2/4540/460
FallInjury, poisoning and procedural complications2/4540/460
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/4540/460
VomitingGastrointestinal disorders1/4542/460
Most frequent other events
Most frequent other events
EventInsulin Degludec (IDeg)Insulin Glargine (IGlar)
NasopharyngitisInfections and infestations68/45461/460
Upper respiratory tract infectionInfections and infestations29/45439/460

Baseline characteristics

Baseline results are based on the full analysis set (FAS), which included all randomised subjects.

Age, Continuous
Age, Continuous(years)Insulin Degludec/Insulin Glargine (IDeg/IGlar)Insulin Glargine/Insulin Degludec (IGlar/IDeg)Total
Mean45.4 ± 13.746.4 ± 14.645.9 ± 14.2
Sex: Female, Male
Sex: Female, Male(Participants)Insulin Degludec/Insulin Glargine (IDeg/IGlar)Insulin Glargine/Insulin Degludec (IGlar/IDeg)Total
Female123109232
Male126143269
Glycosylated hemoglobin (HbA1c)
Glycosylated hemoglobin (HbA1c)(Percentage of HbA1c)Insulin Degludec/Insulin Glargine (IDeg/IGlar)Insulin Glargine/Insulin Degludec (IGlar/IDeg)Total
Mean7.7 ± 1.07.5 ± 1.07.6 ± 1.0
Fasting plasma glucose (FPG)
Fasting plasma glucose (FPG)(mg/dL)Insulin Degludec/Insulin Glargine (IDeg/IGlar)Insulin Glargine/Insulin Degludec (IGlar/IDeg)Total
Mean165.1 ± 77.3174.4 ± 81.7169.8 ± 79.6
09

Study locations

99 sites
  • Novo Nordisk Investigational Site
    Birmingham, Alabama 35215-7502, United States
  • Novo Nordisk Investigational Site
    Goodyear, Arizona 85395, United States
  • Novo Nordisk Investigational Site
    Concord, California 94520, United States
  • Novo Nordisk Investigational Site
    Escondido, California 92025, United States
  • Novo Nordisk Investigational Site
    Fresno, California 93720, United States
  • Novo Nordisk Investigational Site
    La Jolla, California 92037, United States
  • Novo Nordisk Investigational Site
    Long Beach, California 90807, United States
  • Novo Nordisk Investigational Site
    Rancho Cucamonga, California 91730-3063, United States
  • Novo Nordisk Investigational Site
    San Mateo, California 94401, United States
  • Novo Nordisk Investigational Site
    San Ramon, California 94583, United States
  • Novo Nordisk Investigational Site
    Santa Monica, California 90404, United States
  • Novo Nordisk Investigational Site
    Upland, California 91786, United States
  • Novo Nordisk Investigational Site
    Ventura, California 93003, United States
  • Novo Nordisk Investigational Site
    Denver, Colorado 80220, United States
  • Novo Nordisk Investigational Site
    Cooper City, Florida 33024, United States
  • Novo Nordisk Investigational Site
    Fleming Island, Florida 32003, United States
  • Novo Nordisk Investigational Site
    Fort Lauderdale, Florida 33312, United States
  • Novo Nordisk Investigational Site
    Hialeah, Florida 33012, United States
  • Novo Nordisk Investigational Site
    Jacksonville, Florida 32204, United States
  • Novo Nordisk Investigational Site
    Jacksonville, Florida 32207, United States
  • Novo Nordisk Investigational Site
    Jacksonville, Florida 32216, United States
  • Novo Nordisk Investigational Site
    Jacksonville, Florida 32256, United States
  • Novo Nordisk Investigational Site
    Miami Springs, Florida 33166, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33130, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33156, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33175, United States
  • Novo Nordisk Investigational Site
    New Port Richey, Florida 34652, United States
  • Novo Nordisk Investigational Site
    Pembroke Pines, Florida 33026, United States
  • Novo Nordisk Investigational Site
    Port Charlotte, Florida 33952, United States
  • Novo Nordisk Investigational Site
    Port Orange, Florida 32127, United States
  • Novo Nordisk Investigational Site
    Lawrenceville, Georgia 30046, United States
  • Novo Nordisk Investigational Site
    Idaho Falls, Idaho 83404-7596, United States
  • Novo Nordisk Investigational Site
    Arlington Heights, Illinois 60005-4144, United States
  • Novo Nordisk Investigational Site
    Chicago, Illinois 60611, United States
  • Novo Nordisk Investigational Site
    Crystal Lake, Illinois 60012, United States
  • Novo Nordisk Investigational Site
    Skokie, Illinois 60077, United States
  • Novo Nordisk Investigational Site
    Anderson, Indiana 46011, United States
  • Novo Nordisk Investigational Site
    Indianapolis, Indiana 46234, United States
  • Novo Nordisk Investigational Site
    Council Bluffs, Iowa 51501, United States
  • Novo Nordisk Investigational Site
    West Des Moines, Iowa 50265, United States
  • Novo Nordisk Investigational Site
    Lenexa, Kansas 66219, United States
  • Novo Nordisk Investigational Site
    Topeka, Kansas 66606, United States
  • Novo Nordisk Investigational Site
    Lexington, Kentucky 40503, United States
  • Novo Nordisk Investigational Site
    Livonia, Michigan 48152, United States
  • Novo Nordisk Investigational Site
    Hazelwood, Missouri 63042, United States
  • Novo Nordisk Investigational Site
    Jefferson City, Missouri 65109, United States
  • Novo Nordisk Investigational Site
    Kansas City, Missouri 64106, United States
  • Novo Nordisk Investigational Site
    Billings, Montana 59101, United States
  • Novo Nordisk Investigational Site
    Omaha, Nebraska 68114, United States
  • Novo Nordisk Investigational Site
    Henderson, Nevada 89052-2649, United States
  • Novo Nordisk Investigational Site
    Las Vegas, Nevada 89148, United States
  • Novo Nordisk Investigational Site
    Nashua, New Hampshire 03063, United States
  • Novo Nordisk Investigational Site
    Hamilton, New Jersey 08690, United States
  • Novo Nordisk Investigational Site
    Albany, New York 12206, United States
  • Novo Nordisk Investigational Site
    Harrison, New York 10528, United States
  • Novo Nordisk Investigational Site
    Mineola, New York 11501, United States
  • Novo Nordisk Investigational Site
    Syracuse, New York 13210, United States
  • Novo Nordisk Investigational Site
    Asheville, North Carolina 28803, United States
  • Novo Nordisk Investigational Site
    Greenville, North Carolina 27834, United States
  • Novo Nordisk Investigational Site
    Morehead City, North Carolina 28557, United States
  • Novo Nordisk Investigational Site
    Raleigh, North Carolina 27609, United States
  • Novo Nordisk Investigational Site
    Toledo, Ohio 43614, United States
  • Novo Nordisk Investigational Site
    Oklahoma City, Oklahoma 73104, United States
  • Novo Nordisk Investigational Site
    Jenkintown, Pennsylvania 19046, United States
  • Novo Nordisk Investigational Site
    Philadelphia, Pennsylvania 19107, United States
  • Novo Nordisk Investigational Site
    Pittsburgh, Pennsylvania 15224-2215, United States
  • Novo Nordisk Investigational Site
    Chattanooga, Tennessee 37411, United States
  • Novo Nordisk Investigational Site
    Kingsport, Tennessee 37660, United States
  • Novo Nordisk Investigational Site
    Amarillo, Texas 79106, United States
  • Novo Nordisk Investigational Site
    Austin, Texas 78731, United States
  • Novo Nordisk Investigational Site
    Austin, Texas 78758, United States
  • Novo Nordisk Investigational Site
    Carrollton, Texas 75007, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75231, United States
  • Novo Nordisk Investigational Site
    El Paso, Texas 79912, United States
  • Novo Nordisk Investigational Site
    Houston, Texas 77024, United States
  • Novo Nordisk Investigational Site
    Houston, Texas 77079, United States
  • Novo Nordisk Investigational Site
    Katy, Texas 77450, United States
  • Novo Nordisk Investigational Site
    Mesquite, Texas 75149, United States
  • Novo Nordisk Investigational Site
    Richardson, Texas 75080, United States
  • Novo Nordisk Investigational Site
    San Antonio, Texas 78229, United States
  • Novo Nordisk Investigational Site
    Schertz, Texas 78154, United States
  • Novo Nordisk Investigational Site
    Sugar Land, Texas 77478, United States
  • Novo Nordisk Investigational Site
    Salt Lake City, Utah 84102, United States
  • Novo Nordisk Investigational Site
    Salt Lake City, Utah 84107, United States
  • Novo Nordisk Investigational Site
    Chesapeake, Virginia 23321, United States
  • Novo Nordisk Investigational Site
    Norfolk, Virginia 23510, United States
  • Novo Nordisk Investigational Site
    Federal Way, Washington 98003, United States
  • Novo Nordisk Investigational Site
    Renton, Washington 98057, United States
  • Novo Nordisk Investigational Site
    Richland, Washington 99352, United States
  • Novo Nordisk Investigational Site
    Spokane, Washington 99208, United States
  • Novo Nordisk Investigational Site
    Walla Walla, Washington 99362-4445, United States
  • Novo Nordisk Investigational Site
    Milwaukee, Wisconsin 53209, United States
  • Novo Nordisk Investigational Site
    Bialystok, 15-435, Poland
  • Novo Nordisk Investigational Site
    Gdansk, 80-546, Poland
  • Novo Nordisk Investigational Site
    Gdansk, 80-858, Poland
  • Novo Nordisk Investigational Site
    Szczecin, 70-506, Poland
  • Novo Nordisk Investigational Site
    Warszawa, 04-736, Poland
  • Novo Nordisk Investigational Site
    Zabrze, 41-800, Poland
  • Novo Nordisk Investigational Site
    Manati, 00674, Puerto Rico
10

References and documents

Publications

  • Lane W, Bailey TS, Gerety G, Gumprecht J, Philis-Tsimikas A, Hansen CT, Nielsen TSS, Warren M; Group Information; SWITCH 1. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial. JAMA. 2017 Jul 4;318(1):33-44. doi: 10.1001/jama.2017.7115. PubMed 28672316 ↗
  • Evans M, Mehta R, Gundgaard J, Chubb B. Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine U100 in Type 1 and Type 2 Diabetes Mellitus in a UK Setting. Diabetes Ther. 2018 Oct;9(5):1919-1930. doi: 10.1007/s13300-018-0478-1. Epub 2018 Aug 10. PubMed 30097995 ↗
  • DeVries JH, Bailey TS, Bhargava A, Gerety G, Gumprecht J, Heller S, Lane W, Wysham CH, Zinman B, Bak BA, Hachmann-Nielsen E, Philis-Tsimikas A. Day-to-day fasting self-monitored blood glucose variability is associated with risk of hypoglycaemia in insulin-treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials. Diabetes Obes Metab. 2019 Mar;21(3):622-630. doi: 10.1111/dom.13565. Epub 2018 Nov 26. PubMed 30362250 ↗
11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2014 to primary completion in Jan 2016, 24 months.

Results were first posted in May 2017, 1 year 4 months after primary completion.

Of 79 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 24. This study's 24 months is above that.

Counting every sponsor, half of 108 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2014
First posted
Jan 13, 2014
StartActual
Jan 5, 2014
Primary completionActual
Jan 11, 2016
CompletionActual
Jan 11, 2016
Results first posted
May 15, 2017
Last update
Jan 2, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 2, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02034513
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jan 13, 2014
Start date
Jan 5, 2014
Primary completion
Jan 11, 2016
Completion
Jan 11, 2016
Results posted
May 15, 2017
Last update
Jan 2, 2019

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin degludec · Insulin Glargine · Insulin Aspart

Start the discussion